What You'll Learn
Table of Contents
Weeks 1–4: Escalation, Not Results
These medications start at a dose well below the therapeutic one and escalate over weeks. That is deliberate: the gastrointestinal effects cluster around dose increases, and starting at a full dose would make them intolerable.
The practical consequence is that the first month is mostly about tolerating the drug, not losing weight. Some people lose a few kilograms — often partly water — and some lose almost nothing. Neither predicts the eventual outcome.
Pooling STEP 1–3 (semaglutide 2.4 mg, n=2,117; placebo, n=1,262), the most reported gastrointestinal events were nausea (43.9% vs 16.1%), diarrhoea (29.7% vs 15.9%), vomiting (24.5% vs 6.3%) and constipation (24.2% vs 11.1%). 99.5% of events were non-serious and 98.1% mild-to-moderate, occurring most often during or shortly after dose escalation.
PubMed PMID: 34514682 ↗Bottom line: Judging whether the medication is working from month one is judging a titration schedule. There is nothing to read yet.
Months 2–4: The Curve Steepens
As the dose reaches therapeutic levels, appetite suppression becomes properly established and the rate of loss picks up. This is usually when people first notice clothes fitting differently.
It is also when the habits that determine the quality of the loss get set. Protein intake and training established now carry through the whole course; established at month nine, they are catching up on months of unnecessary lean-mass loss.
Start the protein target and resistance training here, not later.
Months 5–9: Most Of The Loss
This is the productive stretch. Body-composition data from a semaglutide cohort puts numbers on it:
Fat mass fell 14% at month 7 and 18% at month 12. Lean mass dropped initially (−3 kg at month 7) then stabilised rather than continuing to fall. Handgrip strength improved by 4.5 kg at month 12, and sarcopenic obesity prevalence fell from 49% at baseline to 33%.
Full study on PMC ↗Bottom line: Fat mass fell 14% by month 7. Lean mass dropped early — about 3 kg — and then stabilised rather than continuing down, which is the distinction that matters most in this whole timeline.
HealthRX — physician-supervised GLP-1 care
The schedule on this page is built around dose escalation decided by a provider who is watching how you respond. Without one, there is nobody to make the call at each step.
See what the intake involves →Disclosure: we earn a commission if you start a plan through this link, at no extra cost to you. It does not change what this page says. HealthRX dispenses compounded semaglutide and tirzepatide, which are pharmacy-prepared formulations, not the FDA-approved branded products. Nothing on this page is medical advice — that is what the provider review is for.
Months 10–18: Flattening, Not Stopping
Loss continues but slows markedly. In the same cohort fat mass reached 18% by month 12 — so the five months from 7 to 12 delivered roughly a third of what the first seven did.
This is where people conclude the drug has stopped working. It has not. A smaller body needs less energy, so the same eating pattern produces a smaller deficit — the full explanation is in our plateau guide.
The trials that ran to 72 weeks show substantial totals accumulating precisely because loss continued slowly rather than stopping:
In 579 adults randomised after an intensive lifestyle intervention, additional mean weight change to week 72 was −18.4% with tirzepatide against +2.5% with placebo. Fatigue was reported by 20 participants (7.0%) on tirzepatide and 9 (3.1%) on placebo — raised, but far less common than gastrointestinal effects.
Full study on PMC ↗What The Scale Does Not Show
Weight is one number covering several different changes, and following it alone misleads in both directions.
In that cohort, grip strength — a standard measure of functional capacity — improved by 4.5 kg over 12 months, and sarcopenic obesity prevalence fell from 49% to 33%. Neither of those is visible on a scale.
Track waist measurement, how clothes fit, and if possible a body composition measure. During a period when you are training, the scale can sit still while the thing you actually care about keeps improving.
Why Your Timeline Will Differ
Every number on this page is an average, and the spread around these averages is wide. Response varies with starting weight, the specific medication, the dose reached, how quickly escalation is tolerated, and what you eat and whether you train.
Two things worth holding on to. First, a slower response is not a failed one — our expectations guide covers the range the trials actually found. Second, the shape is consistent even when the magnitude is not: slow start, steep middle, flattening end.
Following the original STEP-1 population after semaglutide was stopped, participants regained weight and the cardiometabolic improvements accrued during treatment reversed toward baseline.
Full study on PMC ↗Important: This is a description of trial averages, not a prediction for you, and it is not a reason to change a dose or a schedule. Titration is a prescriber's decision.
